BizDataDive: Why does a new drug require joint R&D?

By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Use. You can change your cookie settings through your browser. China has a third of the world's innovative drugs-in-development, while the US contributes 55% of global biopharma R&D investment. When these strengths meet, multi-billion-dollar partnerships follow—and patients worldwide benefit. In this episode, we explore why drug development knows no borders.

Read the full article at the source →